Abstract 446: Embryonic ectoderm development protein (EED) inhibitor APG-5918 exhibits potent antitumor activity and synergizes with androgen receptor (AR) inhibitor enzalutamide in preclinical prostate cancer (PCa) models
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-446
Abstract: Frequent PRC2 dysregulation in PCa is associated with poor prognosis. As a core PRC2 component, EED is essential for histone methyltransferase activity. The potential antitumor effects of APG-5918 in combination with enzalutamide were evaluated in… read more here.
Keywords: apg 5918; pca; inhibitor; antitumor activity ... See more keywords
Abstract 7189: EED inhibitor APG-5918 renders vulnerability to immunotherapy by rewiring sphingolipid metabolism via nSMase2-ceramide pathway in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-7189
Abstract: Pancreatic cancer has a poor prognosis and is primary resistant to immune checkpoint inhibitors (ICIs) partially due to the inhibitory immune microenvironment. To improve the responsiveness of pancreatic cancer to ICIs, researchers have explored various… read more here.
Keywords: cancer; apg 5918; eed inhibitor; inhibitor apg ... See more keywords
Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Demonstrates Robust Antitumor Activity in Preclinical Models of T-Cell Lymphomas (TCLs)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202655
Abstract: Introduction TCLs encompass a heterogeneous group of hematologic neoplasms derived from clonal proliferation of T lymphocytes and are often characterized by aggressive clinical behavior and poor prognosis. Enhancer of zeste homolog 2 (EZH2), as a… read more here.
Keywords: apg 5918; apg; cell; tcls ... See more keywords